Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Coherus Oncology (CHRS) over the last 5 years, with Q3 2025 value amounting to $241.3 million.

  • Coherus Oncology's Receivables - Other rose 67222.56% to $241.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $241.3 million, marking a year-over-year increase of 67222.56%. This contributed to the annual value of $11.0 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Coherus Oncology's Receivables - Other stood at $241.3 million, which was up 67222.56% from $114.5 million recorded in Q2 2025.
  • Coherus Oncology's Receivables - Other's 5-year high stood at $241.3 million during Q3 2025, with a 5-year trough of $1.9 million in Q1 2025.